Plesner assists UNION therapeutics A/S in acquisition of compound series from LEO Pharma A/S
On 21 July 2020, UNION therapeutics announced the acquisition of the global rights for the LEO PDE4 inhibitor compound series, a series of PDE4 inhibitors discovered by LEO Pharma.
Plesner assisted UNION therapeutics in connection with the acquisition of the compound series, which after the transaction is to be re-named UNI500.
With the acquisition, UNION therapeutics substantially accelerates its growth trajectory, enabling the company to take advantage of synergies at organizational, financial and commercial levels.
UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.
UNION therapeutics will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.
UNION therapeutics is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION therapeutics is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.